Imagen de Portada

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	WenXian OuYang, ShuangJie Li, Songxu Peng
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
por: Jing Li, et al.
Publicado: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
por: Hyeyeon Hong, et al.
Publicado: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
por: Chen‐Pi Li, et al.
Publicado: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
por: Jian Wang, et al.
Publicado: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
por: Jianrong Li, et al.
Publicado: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
por: Eiichi Ogawa
Publicado: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
por: Lukas Burghart, et al.
Publicado: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
por: Elliot B. Tapper, et al.
Publicado: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
por: Yen‐Chun Liu, et al.
Publicado: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
por: Ami D. Sperber, et al.
Publicado: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
por: Yong‐Hai Zhou, et al.
Publicado: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
por: Kyle Staller, et al.
Publicado: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
por: Jian Wang, et al.
Publicado: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
por: Annalisa Schiepatti, et al.
Publicado: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
por: Na‐Ling Kang, et al.
Publicado: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
por: Matthias Lenfant, et al.
Publicado: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
por: Matthias Lenfant, et al.
Publicado: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2024)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
por: Marcus M. Mücke, et al.
Publicado: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
por: Yaomin Wang, et al.
Publicado: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
por: David Bergman, et al.
Publicado: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
por: Arta Aliu, et al.
Publicado: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
por: Jian Wang, et al.
Publicado: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
por: Akshatha Kiran, et al.
Publicado: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
por: María José García, et al.
Publicado: (2024)

Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply
por: Nina Løn, et al.
Publicado: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply
por: Sagnik Biswas, et al.
Publicado: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
por: Dipesh H. Vasant, et al.
Publicado: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
por: S. K. Bansal, et al.
Publicado: (2024)

Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
por: Irene Ligato, et al.
Publicado: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
por: Philip Vutien, et al.
Publicado: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
por: Zhuo Li, et al.
Publicado: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
por: Eunice X. X. Tan, et al.
Publicado: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
por: Vibeke Strande, et al.
Publicado: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply
por: Rocío Ferreiro‐Iglesias, et al.
Publicado: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)